Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.

@article{Georges2007NonmyeloablativeUD,
  title={Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.},
  author={George E Georges and Michael B. Maris and David G Maloney and Brenda M Sandmaier and Mohamed L Sorror and Judith A Shizuru and Thoralf Lange and Edward D Agura and Benedetto Bruno and Peter A. Mcsweeney and Michael A Pulsipher and Thomas R Chauncey and Marco Mielcarek and Barry E Storer and Rainer F Storb},
  journal={Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation},
  year={2007},
  volume={13 4},
  pages={423-32}
}
The purpose of this study was to determine long-term outcome of unrelated donor nonmyeloablative hematopoietic cell transplantation (HCT) in patients with poor-risk multiple myeloma. A total of 24 patients were enrolled; 17 patients (71%) had chemotherapy-refractory disease, and 14 (58%) experienced disease relapse or progression after previous autologous transplantation. Thirteen patients underwent planned autologous transplantation followed 43-135 days later with unrelated transplantation… CONTINUE READING